{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:22:20Z","timestamp":1793766140161,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.seizure.2025.09.021","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:25:34Z","timestamp":1759217134000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population"],"prefix":"10.1016","volume":"133","author":[{"given":"Xintong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyeong","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0790-9837","authenticated-orcid":false,"given":"Kyoung","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Bong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Heui","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8218-7360","authenticated-orcid":false,"given":"Kensuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-8825","authenticated-orcid":false,"given":"Sunita N","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2761-3306","authenticated-orcid":false,"given":"Jungshin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9504-3980","authenticated-orcid":false,"given":"William E","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4883-1551","authenticated-orcid":false,"given":"Takamichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peimin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-6142","authenticated-orcid":false,"given":"Louis","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.seizure.2025.09.021_bib0001","doi-asserted-by":"crossref","first-page":"e2589","DOI":"10.1002\/brb3.2589","article-title":"The burden of epilepsy and unmet need in people with focal seizures","volume":"12","author":"Ioannou","year":"2022","journal-title":"Brain Behav"},{"issue":"2","key":"10.1016\/j.seizure.2025.09.021_bib0002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/epi4.12050","article-title":"Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil","volume":"2","author":"Gupta","year":"2017","journal-title":"Epilepsia Open"},{"issue":"3","key":"10.1016\/j.seizure.2025.09.021_bib0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0004","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2025.09.021_bib0006","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(12)70188-6","article-title":"Impaired consciousness in epilepsy","volume":"11","author":"Blumenfeld","year":"2012","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2025.09.021_bib0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1528-1167.2006.00666.x","article-title":"Epilepsy-related injuries","volume":"47","author":"Wirrell","year":"2006","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2025.09.021_bib0008","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1474-4422(16)30158-2","article-title":"Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2025.09.021_bib0009","doi-asserted-by":"crossref","unstructured":"Beniczky S., Trinka E., Wirrell E., et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia. 2025;[Epub ahead of print]. https:\/\/doi.org\/10.1111\/epi.18338.","DOI":"10.1111\/epi.18338"},{"key":"10.1016\/j.seizure.2025.09.021_bib0010","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use. CV [prescribing information]. Paramus, NJ: SK Life Science, Inc.; August 2025. https:\/\/www.xcoprihcp.com\/xcopri-hcp-pi-med-guide\/."},{"key":"10.1016\/j.seizure.2025.09.021_bib0011","unstructured":"Ontozry [summary of product characteristics]. Rome, Italy: Angelini Pharma S.p.A.; June 28, 2023."},{"key":"10.1016\/j.seizure.2025.09.021_bib0012","unstructured":"Endo Operations Ltd. XCOPRI cenobamate tablets, 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, oral [product monograph]. 2024. https:\/\/www.endodocuments.com\/XCOPRI\/MONOGRAPH; [accessed July 18, 2024]."},{"key":"10.1016\/j.seizure.2025.09.021_bib0013","unstructured":"Pharmacy & Poisons Board of Hong Kong. XCOPRI tablets 100 mg. 2023. https:\/\/www.drugoffice.gov.hk\/eps\/drug\/productDetail2\/en\/consumer\/142601; [accessed July 19, 2024]."},{"issue":"22","key":"10.1016\/j.seizure.2025.09.021_bib0014","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2025.09.021_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.seizure.2025.09.021_bib0016","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2025.09.021_bib0017","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0018","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/epi.17935","article-title":"A global update on cenobamate based on real-world experience in over 100\u2009000 patients","volume":"65","author":"Ferrari","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.09.021_bib0019","unstructured":"SK Life Science, Inc. Data on file [update: 220,000 patients treated with cenobamate]. 2025."},{"key":"10.1016\/j.seizure.2025.09.021_bib0020","doi-asserted-by":"crossref","unstructured":"Misra S., Ferrari L., Hong Z., et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures, with optional open-label extension [poster]. Presented at the American Epilepsy Society Annual Meeting, December 6-10, 2024, Los Angeles, CA. Poster 1.400. https:\/\/aesnet.org\/abstractslisting\/a-randomized-double-blind-placebo-controlled-multicenter-study-to-evaluate-the-efficacy-and-safety-of-adjunctive-cenobamate-in-asian-patients-with-focal-seizures-with-optional-open-label-extension; [accessed December 7, 2024].","DOI":"10.1212\/WNL.0000000000208538"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0021","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League against Epilepsy","volume":"22","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.09.021_bib0022","unstructured":"International Council for Harmonisation. Guideline for good clinical practice E6(R3). 2025. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf; [accessed June 10, 2025]."},{"issue":"23","key":"10.1016\/j.seizure.2025.09.021_bib0023","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs in Asians","volume":"77","author":"Yang","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.seizure.2025.09.021_bib0024","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.eplepsyres.2014.06.004","article-title":"Efficacy of lacosamide by focal seizure subtype","volume":"108","author":"Sperling","year":"2014","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","article-title":"An update of its pharmacology and therapeutic use in epilepsy","volume":"50","author":"Fitton","year":"1995","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0026","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1996.tb07060.x","article-title":"Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures","volume":"94","author":"Boas","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2025.09.021_bib0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2025.09.021_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.seizure.2025.09.021_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106940","article-title":"Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study","volume":"183","author":"Rosenfeld","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.09.021_bib0030","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"issue":"12","key":"10.1016\/j.seizure.2025.09.021_bib0031","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.09.021_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108270","article-title":"Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy-expert opinion","volume":"123","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2025.09.021_bib0033","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","article-title":"Antiepileptic drugs and liver disease","volume":"15","author":"Ahmed","year":"2006","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.seizure.2025.09.021_bib0034","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/epi4.13018","article-title":"Switching carbamazepine to lacosamide improves gamma-glutamyl transpeptidase levels","volume":"9","author":"Kubota","year":"2024","journal-title":"Epilepsia Open"},{"issue":"1","key":"10.1016\/j.seizure.2025.09.021_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3805\/eands.11.1","article-title":"Effects of antiepileptic monotherapy on hematological and biochemical parameters","volume":"11","author":"Yoshimura","year":"2019","journal-title":"Epilepsy & Seizure"},{"issue":"Pt 3","key":"10.1016\/j.seizure.2025.09.021_bib0036","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/000456329102800322","article-title":"Serum gamma glutamyl transferase activities in epileptic patients receiving carbamazepine monotherapy","volume":"28","author":"Okesina","year":"1991","journal-title":"Ann Clin Biochem"},{"issue":"3","key":"10.1016\/j.seizure.2025.09.021_bib0037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1059-1311(97)80007-6","article-title":"Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy","volume":"6","author":"Isoj\u00e4rvi","year":"1997","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2025.09.021_bib0038","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s43066-022-00230-y","article-title":"COVID-19-associated liver injury, role of drug therapy and management: a review","volume":"12","author":"Iheanacho","year":"2022","journal-title":"Egypt Liver J"},{"issue":"2","key":"10.1016\/j.seizure.2025.09.021_bib0039","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3748\/wjg.v29.i2.257","article-title":"COVID-19 and liver injury: an ongoing challenge","volume":"29","author":"Papagiouvanni","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.seizure.2025.09.021_bib0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","article-title":"Liver injury in COVID-19: management and challenges","volume":"5","author":"Zhang","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0041","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/20014091084227","article-title":"Gamma glutamyl transferase","volume":"38","author":"Whitfield","year":"2001","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.seizure.2025.09.021_bib0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eplepsyres.2016.02.002","article-title":"Response to placebo in clinical epilepsy trials\u2013old ideas and new insights","volume":"122","author":"Goldenholz","year":"2016","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.seizure.2025.09.021_bib0043","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2025.09.021_bib0044","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.09.021_bib0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eplepsyres.2016.09.003","article-title":"Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies","volume":"127","author":"Moseley","year":"2016","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2025.09.021_bib0046","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/epi.16428","article-title":"Efficacy and safety of adjunctive perampanel 4 mg\/d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies","volume":"61","author":"Steinhoff","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.09.021_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106694","article-title":"Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: post hoc pooled analysis","volume":"176","author":"Moseley","year":"2021","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2025.09.021_bib0048","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00415-021-10751-y","article-title":"PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice","volume":"269","author":"Villanueva","year":"2022","journal-title":"J Neurol"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:58:12Z","timestamp":1773259092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"alternative-id":["S1059131125002675"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.09.021","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}